Posted by Michael Wonder on 09 Feb 2026
ICER releases evidence report on therapies for IgA nephropathy
9 February 2026 - All three therapies exhibit net health benefits, but uncertainties remain around the magnitude of long-term improvements in outcomes as well as safety; sibeprenlimab’s price far exceeds usual thresholds for cost effectiveness.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of sibeprenlimab (Voyxact, Otsuka), atacicept (Vera Therapeutics) and delayed release budesonide (“Nefecon”, Tarpeyo, Calliditas Therapeutics) for IgA nephropathy.
